c-Met is a marker of pancreatic cancer stem cells and therapeutic target

C Li, JJ Wu, M Hynes, J Dosch, B Sarkar, TH Welling… - Gastroenterology, 2011 - Elsevier
BACKGROUND & AIMS: Growth of many different tumor types requires a population of self-
renewing cancer stem cells (CSCs). c-Met is a marker of normal mouse pancreatic stem and …

[HTML][HTML] Opportunities and challenges of targeting c-Met in the treatment of digestive tumors

Z Zhang, D Li, H Yun, J Tong, W Liu, K Chai… - Frontiers in …, 2022 - frontiersin.org
At present, a large number of studies have demonstrated that c-Met generally exerts a
crucial function of promoting tumor cells proliferation and differentiation in digestive system …

Prospective isolation of multipotent pancreatic progenitors using flow-cytometric cell sorting

A Suzuki, H Nakauchi, H Taniguchi - Diabetes, 2004 - Am Diabetes Assoc
During pancreatic development, neogenesis, and regeneration, stem cells might act as a
central player to generate endocrine, acinar, and duct cells. Although these cells are well …

Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (Volitinib) as a Highly Potent and Selective …

H Jia, G Dai, J Weng, Z Zhang, Q Wang… - Journal of medicinal …, 2014 - ACS Publications
HGF/c-Met signaling has been implicated in human cancers. Herein we describe the
invention of a series of novel triazolopyrazine c-Met inhibitors. The structure–activity …

Breaking the cycle: targeting of NDRG1 to inhibit bi‐directional oncogenic cross‐talk between pancreatic cancer and stroma

B Geleta, KC Park, PJ Jansson, S Sahni… - The FASEB …, 2021 - Wiley Online Library
Pancreatic cancer (PaCa) is characterized by dense stroma that hinders treatment efficacy,
with pancreatic stellate cells (PSCs) being a major contributor to this stromal barrier and …

HGF/MET signaling in ovarian cancer

HY Zhou, YL Pon, AST Wong - Current molecular medicine, 2008 - ingentaconnect.com
Ovarian cancer is the leading cause of death from gynecological cancers in North America
and Europe. Despite its clinical significance, the factors that regulate the development and …

[HTML][HTML] Selecting tumor-specific molecular targets in pancreatic adenocarcinoma: paving the way for image-guided pancreatic surgery

SWL de Geus, LSF Boogerd, RJ Swijnenburg… - Molecular imaging and …, 2016 - Springer
Purpose The purpose of this study was to identify suitable molecular targets for tumor-
specific imaging of pancreatic adenocarcinoma. Procedures The expression of eight …

A MET Targeting antibody–drug conjugate overcomes gemcitabine resistance in pancreatic cancer

A Cazes, O Betancourt, E Esparza, ES Mose… - Clinical Cancer …, 2021 - AACR
Purpose: Pancreatic cancer is an aggressive disease associated with a poor 5-year overall
survival. Most patients are ineligible for surgery due to late diagnosis and are treated …

Overexpression of the c-met protooncogene in human gastric carcinoma-correlation to clinical features

TJ Huang, JY Wang, SR Lin, ST Lian, JS Hsieh - Acta oncologica, 2001 - Taylor & Francis
Overexpression of hepatocyte growth factor receptor (c-met) has been detected in many
human tumors. To investigate the possible involvement of c-met in human gastric …

[HTML][HTML] Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling

HM Chen, CH Tsai, WC Hung - Oncotarget, 2015 - ncbi.nlm.nih.gov
Foretinib, a multiple kinase inhibitor undergoing clinical trials, could suppress the activity of
hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor …